Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

ClinicalTrials.gov ID: NCT00423046

Public ClinicalTrials.gov record NCT00423046. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]

Study identification

NCT ID
NCT00423046
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,106 participants

Conditions and interventions

Interventions

  • GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) Biological
  • Gardasil ® (Merck & Co. Inc) Biological
  • Placebo Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 45 Years
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 23, 2007
Primary completion
Mar 6, 2008
Completion
May 13, 2012
Last update posted
Jan 1, 2020

2007 – 2012

United States locations

U.S. sites
40
U.S. states
20
U.S. cities
39
Facility City State ZIP Site status
GSK Investigational Site Chandler Arizona 85224
GSK Investigational Site San Diego California 92123
GSK Investigational Site San Francisco California 94115
GSK Investigational Site Vista California 92083
GSK Investigational Site West Covina California 91790
GSK Investigational Site Aurora Colorado 80045
GSK Investigational Site Louisville Colorado 80027
GSK Investigational Site Boynton Beach Florida 33437
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Boise Idaho 83642
GSK Investigational Site Arkansas City Kansas 67005
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Milford Massachusetts 01757
GSK Investigational Site Stevensville Michigan 49127
GSK Investigational Site Chaska Minnesota 55318
GSK Investigational Site Saint Paul Minnesota 55108
GSK Investigational Site Omaha Nebraska 68131
GSK Investigational Site New York New York 10029
GSK Investigational Site The Bronx New York 10461
GSK Investigational Site Chapel Hill North Carolina 27514
GSK Investigational Site Cincinnati Ohio 45249
GSK Investigational Site Cleveland Ohio 44122
GSK Investigational Site Willoughby Hills Ohio 44094
GSK Investigational Site Carnegie Pennsylvania 15106
GSK Investigational Site Erie Pennsylvania 16507
GSK Investigational Site Erie Pennsylvania 16508
GSK Investigational Site Lancaster Pennsylvania 17601
GSK Investigational Site Philadelphia Pennsylvania 19107
GSK Investigational Site Upper Saint Clair Pennsylvania 15241
GSK Investigational Site Warwick Rhode Island 02886
GSK Investigational Site Austin Texas 78705
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Salt Lake City Utah 84109
GSK Investigational Site Tacoma Washington 98418
GSK Investigational Site Walla Walla Washington 99362
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00423046, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 1, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00423046 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →